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Abstract
Background: There is a significant variation among individual primary care providers in prescribing of potentially
problematic, low-value medicines which cause avoidable patient harm. Audit and feedback is generally effective at
improving prescribing. However, progress has been hindered by research waste, leading to unanswered questions
about how to include audit and feedback for specific problems and circumstances. Trials of different ways of
providing audit and feedback in implementation laboratories have been proposed as a way of improving
population healthcare while generating robust evidence on feedback effects. However, there is limited experience
in their design and delivery.
Aim: To explore priorities, feasibility, and ethical challenges of establishing a primary care prescribing audit and
feedback implementation laboratory.
Design and setting: Two-stage Delphi consensus process involving primary care pharmacy leads, audit and
feedback researchers, and patient and public.
Method: Participants initially scored statements relating to priorities, feasibility, and ethical considerations for an
implementation laboratory. These covered current feedback practice, priority topics for feedback, usefulness of
feedback in improving prescribing and different types of prescribing data, acceptability and desirability of different
organization levels of randomization, options for trial consent, different methods of delivering feedback, and
interest in finding out how effective different ways of presenting feedback would be. After receiving collated
results, participants then scored the items again. The consensus was defined using the GRADE criteria. The results
were analyzed by group and overall score.
Results: Fourteen participants reached consensus for 38 out of 55 statements. Addressing antibiotic and opioid
prescribing emerged as the highest priorities for action. The panel supported statements around addressing high-
priority prescribing issues, taking an “opt-out” approach to practice consent if waiving consent was not permitted,
and randomizing at lower rather than higher organizational levels. Participants supported patient-level prescribing
data and further research evaluating most of the different feedback methods we presented them with.
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Conclusions: There is a good level of support for evaluating a wide range of potential enhancements to improve the
effects of feedback on prescribing. The successful design and delivery of a primary care audit and feedback
implementation laboratory depend on identifying shared priorities and addressing practical and ethical considerations.
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Contributions to the literature
 There is significant variation among individual primary care
providers in prescribing of potentially harmful, problematic
medicines.
 Audit and feedback appears effective at improving
prescribing in primary care; however, there is limited
knowledge on how to improve its effectiveness.
 A primary care prescribing implementation laboratory has
been suggested as a potential solution with opportunities
for researchers and healthcare systems to conduct
embedded collaborative research to increase impact and
effectiveness.
 Expert recommendations on how to optimize the design of
a primary care prescribing audit and feedback
implementation laboratory include addressing high-priority
prescribing issues, opt-out consent for practices, access to
detailed prescribing data, and randomization at lower rather
than higher organizational levels.
 Establishing a primary care prescribing implementation
laboratory depends on identifying shared priorities and
addressing practical and ethical considerations.
Introduction
There is a significant variation among primary care
providers in potentially harmful and relatively ineffect-
ive prescribing [1–4]. Prescribing of medicines such as
antibiotics, opioids, anticholinergics, and non-steroidal
anti-inflammatory drugs (NSAIDs) is associated with
wide-ranging harms, including increased mortality,
hospitalization, falls, dependence, and antimicrobial
resistance [3, 5, 6]. It also represents poor value for
money in resource-constrained healthcare systems [7].
A range of approaches has been used to address problem-
atic prescribing, including financial incentives, electronic
decision support tools, and educational outreach [1, 8, 9].
Audit and feedback is often used as a core component of
these approaches; it aims to improve patient care through
collecting and feeding back performance data to providers
[10]. Feedback may improve prescribing in several ways, in-
cluding alerting providers to the need for action, encour-
aging providers to think twice before initiating medicines,
and triggering structured reviews to rationalize medicines
for individual patients [1]. Audit and feedback offers the
relative efficiencies of harnessing routine electronic health
record data, often available for prescribing [11] and having
a wide population reach. High-performing health systems
tend to feature audit and feedback as an evidence-based,
scalable, and relatively inexpensive strategy to encourage
uptake of best practice [12].
Audit and feedback is generally modestly effective. A
Cochrane review of 140 randomized trials found that
audit and feedback produced a median of 4.3% absolute
improvement in processes of care, such as prescribing
[10]. However, there is a wide variation in effectiveness.
A quarter of audit and feedback interventions had rela-
tively large, positive effects of up to 16% while another
quarter had no or even negative effects. Feedback effects
are generally greater when the source is a supervisor or
colleague, it is provided more than once, it is delivered
in both verbal and written formats, and it includes both
explicit targets for change and action plans. However,
there are still many uncertainties about how to optimize
audit and feedback [13]. Progress has been hindered by
research waste in this field through a lack of cumulative
learning from duplicative trials of audit and feedback
[14]. This means that those responsible for designing
and delivering quality improvement programs will con-
tinue to have unanswered questions about how to include
audit and feedback for specific problems and circum-
stances [14].
To understand when audit and feedback is most likely
to be effective and how to optimize it, we need to move
away from two-arm trials of audit and feedback compared
with control in favor of head-to-head trials of different
ways of providing audit and feedback. Implementation
laboratories use a learning health system approach, involv-
ing collaborations between healthcare organizations
providing audit and feedback at scale, and researchers, to
embed head-to-head trials into quality improvement pro-
grams. Implementation laboratories have been proposed
to improve the impact of audit and feedback while simul-
taneously producing generalizable knowledge about how
to optimize the effects of such quality improvement initia-
tives [15]. A “radical incrementalism” approach involves
making sequential, small changes, supported by tightly
focused evaluations to cumulatively improve outcomes.
It is already used in public policy and in business. For
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example, Amazon and Google randomize potential
customers to different presentations of their products
online to understand what drives purchases. It is also
highly applicable to healthcare [16]. While trials of dif-
ferent feedback methods have been embedded within
existing audit programs [17], there is still limited ex-
perience in establishing audit and feedback implemen-
tation laboratories.
Our earlier work involved interviewing primary care
staff (physicians, nurses, and managers) about a range of
evidence-based recommendations and involved primary
care physicians in developing an implementation pack-
age that included audit and feedback [18]. The interven-
tion package successfully reduced high-risk prescribing
in primary care [19]. Interviews with primary care physi-
cians and prescribing data identified opioid prescribing
as a high-priority topic for improvement [4, 20]. We
adapted this feedback intervention and delivered a 1-
year feedback campaign on opioid prescribing in primary
care. Our controlled interrupted time-series analysis
found that the number of adults prescribed any opioid
(excluding those with coded cancer diagnoses) fell dur-
ing the intervention year [Alderson SL, Farragher TM,
Willis TA, Carder P, Johnson S, Foy R: The effects of an
evidence and theory-informed feedback intervention on
opioid prescribing for non-cancer pain in primary care: a
controlled interrupted time series analysis. Submitted.].
We interviewed physicians and found our feedback cam-
paign was well-received by practices and worked by
alerting prescribers to the need for action, prompting
prescribers to think twice before initiating opioids, and
encouraging medication reviews of patients who may
not benefit from opioids [Wood S, Foy R, Willis TA,
Carder P, Johnson S, Alderson SL: General practice re-
sponses to opioid prescribing feedback: a qualitative
process evaluation. Submitted.]. We also identified re-
mediable weaknesses.
We are planning an audit and feedback implementa-
tion laboratory to address high-priority prescribing
issues in primary care in the UK. Our overall program of
work is strongly embedded in the primary care physicians’
perspectives and experiences. In this study, we sought wider
service, research and public perspectives on prescribing pri-
orities, and the feasibility and ethical challenges of establish-
ing an implementation laboratory [21].
Methods
We used a two-stage Delphi consensus development
process [22] to define key features of the planned imple-
mentation laboratory. The Delphi method is an iterative
process which involves collecting, analyzing, and sharing
the anonymous opinions of key stakeholders. It is useful
when there is incomplete knowledge about a problem,
particularly when the goals are to improve understand-
ing and suggest solutions [22].
We identified potential participants as local primary
care pharmacy leads responsible for medicine optimization
in primary care, international audit and feedback re-
searchers (affiliated to the Audit and Feedback Metalab
[19]), and an existing primary care Patient and Public
Involvement and Engagement (PPIE) panel with prior
experience in implementation research [23]. This would en-
sure that our Delphi process would account for service, re-
search, and public perspectives. We planned for 15–30
panelists in considering likely reliability and feasibility [22].
There is no agreement about the optimal size of a Delphi
panel, with many including under 20 people [24, 25].
Using online surveys [26], we presented participants
with questions and statements around priorities for an im-
plementation laboratory and feasibility and ethical consid-
erations (Additional file 1). These covered the following:
 Current feedback practice—how feedback on
prescribing is currently delivered to primary care
practices (for medicine optimization leads only)
 Priority topics for feedback—offering six options of
antibiotic prescribing, opioids for chronic non-
cancer pain, gabapentinoids, anticholinergic burden,
prescribing safety indicators, and prescribing in low
kidney function
 Perceived usefulness of audit and feedback in
improving prescribing and importance of improving
its effectiveness
 Perceived usefulness of different types of prescribing
data, such as total numbers of prescriptions,
numbers of patients prescribed medicines, and
numbers of patients in high-risk subgroups pre-
scribed medicines
 Acceptability of different levels of randomization—at
four levels of practices, practice networks (small
groups of practices covering 50,000 patients), clinical
commissioning group (larger area-wide groups of
practices with responsibility for commissioning
healthcare), and sustainability and transformation
plan (44 larger geographical areas covering NHS
England, now referred to as integrated care systems)
 Acceptability and desirability of options for trial
consent—including “opt-in” consent for primary
care practices, “opt-out” consent for practices (so
that they would be included in any trial by default
unless they actively decline), consent at higher
organizational levels (clinical commissioning group
or sustainability and transformation plan), and
waiving of consent
 Acceptability and desirability of different methods of
delivering feedback—such as paper-based hard
copies, emailed PDFs, or online dashboards
Alderson et al. Implementation Science Communications             (2021) 2:3 Page 3 of 10
 Interest in finding out how effective different ways
of delivering feedback would be—such as using
different comparators, visual presentations, and
additional education outreach and training
We drew on previous work describing potential chal-
lenges in setting up implementation laboratories and team
brainstorming [13, 15, 21]. We piloted the statements with
two feedback researchers and three medicine optimization
professionals. For most statements, participants could rate
according to one or more of importance (potential to im-
prove patient safety and care), priority (based on whether
there are existing interventions to improve safety and
care), usefulness (to primary care providers), acceptability,
and desirability (for research purposes). Statements were
rated on a 1–9 scale, where “1” indicated the strongest
disagreement and “9” the strongest agreement. We also
provided an “unable to score” response if participants felt
unable to rate a statement. Participants could also com-
ment on the rationale for their decisions. We asked partic-
ipants to complete the survey independently in round 1.
Support for a statement was defined as 70% or more of re-
sponses scoring ≥ 7 and 15% or less responses rating the
outcome ≤ 3.
We removed statements rejected as “not important”
for round 2 to maximize efficiency. The remaining state-
ments were then fed back to all participants via email.
We showed each participant their own scores from
round 1, as well as the median scores from all partici-
pants and for each of the three stakeholder groups [22].
Participants then independently re-rated each statement
[27]. We analyzed the final responses for all participants
and by each stakeholder group.
The University of Leeds School of Medicine Research
Ethics Committee approved the study (ref no: MREC
18-049).
Results
Fourteen participants comprised eight females and six
males, five medicine optimization leads, five feedback re-
searchers (two from The Netherlands, two from Canada,
and one from the USA), and four PPIE panelists out of 15,
52, and 10 invited, respectively (Table 1). All completed
rounds 1 and 2, with a 100% completion rate (Fig. 1).
The medicine optimization leads reported considerable
variability in the current prescribing feedback practice
for primary care (Additional file 2). While all reported
using a comparator, none reported using an online
dashboard (linked or not to electronic health records),
posting paper reports, nor initially providing intense
feedback before reducing frequency.
Eighteen out of 55 statements were supported in
round 1 (Additional file 3). All 55 statements were taken
forward to round 2 as no statement reached the thresh-
old for rejection. Thirty-eight statements were supported
in round 2 (Table 2), while eleven had no clear support.
Prescribing priorities
All prescribing options, except gabapentinoids, were
rated as important, and priorities for improvement, with
antibiotics and opioids for chronic, non-cancer pain,
rated as the highest priority (100% and 93%, respect-
ively). All panelists agreed that feedback interventions
were both useful (86%) and important (93%) as a method
to improve primary care prescribing.
Ethical issues
The panel agreed including all primary care practices
unless they actively withdrew from the implementation
laboratory (opt-out) was both the most acceptable
(100%) and desirable (86%) approach to consent. Indi-
vidual practice consent (opt-in) was considered neither
acceptable (36%) nor desirable (14%). Although waiving
consent was agreed as desirable for recruitment (77%),
the medicine optimization leads were uncertain about
acceptability (62%). Consent at higher organizational
levels (clinical commissioning group or Sustainability
and Transformation Plan) for data access was less ac-
ceptable (68%; 36%) or desirable (77%; 64%).
The majority agreed that primary care providers
(100%), primary care pharmacists (93%), and medicine
optimization leads (92%) should be involved in designing
feedback reports to improve primary care prescribing.
The panelists considered that clinical commissioning
(46%) and PPIE involvement (36%) were less useful.
Feasibility issues
The panel considered the feedback of specific data, such
as subgroups of high-risk patients (100%) or excluding
patients not targeted by the feedback (86%), as the most
useful for changing clinical practice. Less specific data,
Table 1 Characteristics of participants










Audit and feedback researcher 5 (36)
Medicine optimization lead 5 (36)
Patient and public involvement and engagement 4 (28)
Alderson et al. Implementation Science Communications             (2021) 2:3 Page 4 of 10
such as the total number of prescriptions of a medica-
tion, was not considered useful (7%).
For an implementation laboratory, randomization
levels at the local level (practice or primary care net-
work) were the most ideal (100%; 91%). Randomization
by larger areas such as Sustainability and Transform-
ation Plan level was not ideal (63%).
Online dashboards that connected to the electronic
health record system were both acceptable (100%) and
desirable (100%); dashboards unconnected to the elec-
tronic health record system received less support (64%;
79%). Providing multiple paper copies or emailing PDFs
of feedback reports were considered neither desirable
(2%; 7%) nor acceptable (21%; 43%).
Seven out of eight suggested methods of presenting
feedback were agreed as priorities for the implementa-
tion laboratory for further effectiveness evaluations. The
statements “whether feedback identifying specific behav-
iors to be changed is more effective” (93%) and “whether
different comparators within the reports are more effect-
ive” (79%) received the strongest support. Determining
“whether asking practitioners to document the implica-
tions of changing practice is more effective” was not
recommended for testing (43%).
Discussion
We have identified prescribing priorities and elicited
key ethical and feasibility considerations to guide the
establishment of a primary care prescribing implemen-
tation laboratory. All participants agreed that audit and
feedback is both useful and important as a method to
improve primary care prescribing. There is a notable
support to evaluate a wide range of potential enhance-
ments to improve the effects of feedback on prescribing,
which collectively could be addressed by sequential trials
within an implementation laboratory.
The panel supported action on a range of problems,
prioritizing reductions in prescribing of antibiotics and
opioids for chronic, non-cancer pain. Both are recog-
nized internationally as public health threats, with re-
spective legacies of antibiotic resistance and dependence
[4, 28]. Other problems deemed as highly important,
such as prescribing safety indicators, were rated lower as
priorities, given existing quality improvement work.
Detailed prescribing data was preferred, specifically pa-
tients at high risks of dose escalation and adverse effects,
and excluding those patients not targeted by the feedback
[20]. Extracting this data requires access to electronic
health record systems and data sharing agreements,
Fig. 1 Flowchart of the consensus process
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Table 2 Recommendations for a primary care prescribing implementation laboratory
No. Recommendation A&F researcher’s
(n = 5) score (1–9)
Medicine
optimization lead’s




(n = 4) score (1–9)
% Consensus
(n = 14)
Prescribing issues for A&F
Importance
1. Antibiotic prescribing 9 9 8.5 93
2. Prescribing safety indicators 7 8 7.5 93
3. Opioid medication for chronic, non-cancer pain 9 9 7 86
4. Anticholinergic burden 6 8 7 79
5. Prescribing in low kidney function 8 7 6.5 72
6. Gabapentin and pregabalin painkillers 5 8 6 72
Priority
7. Antibiotic prescribing 9 9 8.5 100
8. Opioid medication for chronic, non-cancer pain 9 8.5 7.5 93
9. Anticholinergic burden 7.5 7 7 86
10. Prescribing safety indicators 7.5 7 7.5 79
11. Prescribing in low kidney function 7.5 6 6.5 72
Gabapentin and pregabalin painkillers 6.5 9 8 67
Audit and feedback as a method to improve primary
care prescribing
12. Importance 8 8 9 93
13. Usefulness 8 8 7 86
Usefulness of the types of data
14. Subgroups of patients at high risk of dose
escalation or adverse effects
8 9 9 100
15. Number of patients taking opioid medication,
excluding patients with a palliative care
diagnosis
6.5 8 7.5 86
16. Number of patients taking opioid medication,
excluding patients taking medication for drug
addiction
6 8 8 73
Specific opioid medications 7 7 7 50
Number of patients taking opioid medication 5 6 7.5 50
Total number of opioid prescriptionsa 3 3 3.5 7
Randomization level
17. Randomization at the practice level 9 9 9 100
18. Randomization at the primary care network
level
9 9 8 91
19. Randomization at the clinical commissioning
group level
8 8 7.5 75
Randomization at the Sustainability and
Transformation Plan level
9 7 8 63
Consent
Acceptable
20. Provide practices information on the trial and
allow them to withdraw from the trial if they
wish (practice opt-out)
9 9 9 100
Consent at the clinical commissioning group level
for data access
6 8 7.5 68
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Table 2 Recommendations for a primary care prescribing implementation laboratory (Continued)
No. Recommendation A&F researcher’s
(n = 5) score (1–9)
Medicine
optimization lead’s




(n = 4) score (1–9)
% Consensus
(n = 14)
Waive consent as the burden of responding to
consent request is higher than taking part in
the trial
7 6 8 62
Consent practices individually, asking them to
sign up to an opioid prescribing feedback trial
(practice opt-in)
7 5 6.5 36
Consent at the Sustainability and Transformation
Plan level for data access
6 6 6 36
Ideal
21. Provide practices information on the trial and
allow them to withdraw from the trial if they
wish (practice opt-out)
8 8 8 86
22. Waive consent as the burden of responding to
consent request is higher than taking part in
the trial
8 9 8 77
23. Consent at the clinical commissioning group
level for data access
7 8 4.5 77
Consent at the Sustainability and Transformation
Plan level for data access
6 7 6.5 64
Consent practices individually, asking them to
sign up to an opioid prescribing feedback trial
(practice opt-in)
5 2 5.5 14
Feedback delivery method
Acceptable
24. Have an online dashboard that practices can
log into that connects to the EHR to identify
patients where a review is needed
9 9 9 100
Have an online dashboard that practices can log
into to view their report
(not linked to the EHR system)
7 7 7.5 64
Send a PDF copy of the report via email to each
practice
6 6 6.5 43
Provide (multiple) copies of a paper-based report
to each practice
6 3 4 21
Ideal
25. Have an online dashboard that practices can
log into that connects to the EHR to identify
patients where a review is needed
9 9 9 100
26. Have an online dashboard that practices can
log into to view their report (not linked to the
EHR system)
8 7 7 79
Send a PDF copy of the report via email to each
practice
5 5 5.5 7
Provide (multiple) copies of a paper-based report
to each practicea
3 1 2.5 2
Feedback modifications to test for effectiveness
27. Whether feedback identifying specific behaviors
to be changed is more effective
8 8 7.5 93
28. Whether different comparators within the
reports are more effective
8 8 7 86
29. Whether feedback about an individual or
aggregated cases is more effective
7 9 7.5 79
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thereby increasing complexity and hurdles compared to
using current freely available English NHS prescribing
data such as OpenPrescribing.com [29] and ePACT2 [30].
These initiatives and others providing practice-aggregated
prescriptions by medicine category were not helpful for
feedback. Medicines with more than one indication may
be less suitable for feeding back the total number of pre-
scriptions as exceptions are easier to justify [31]. Highlight-
ing smaller high-priority subgroups of patients may avoid
overwhelming practices, causing avoidance and inaction,
than all patients prescribed antibiotics or opioids.
Consenting practices through an opt-out approach
was agreed to be the most acceptable and desirable.
Clinical commissioning group consent or waiving con-
sent completely was desirable, but less acceptable. Waiv-
ing consent to reduce participation burden and
undermining of results is complicated by the current
data protection regulation but may increase participation
of practices not routinely involved in primary care
research and most likely to benefit. This method was
recently used in a UK-wide audit and feedback trial
to reduce antibiotic prescribing [32].
The panel recommended randomization in implemen-
tation laboratory trials should occur at the practice or
primary care network level. Primary care network level
may reduce trial arm contamination as practices increas-
ingly work closer together, share staff, and develop local
quality improvement initiatives [33]. Practice-level
randomization may increase inherent risks of organizational
instability for an implementation laboratory where sequen-
tial trials are likely to occur over a period of years.
The panel recommended feedback using online dash-
boards that connect to the electronic health record system,
although not currently used by medicine optimization
leads. Evidence suggest dashboards providing easily access-
ible and immediate access to information (e.g., as a screen
saver) may improve adherence to recommendations and
improve patient outcomes [34]. Multiple dashboards target-
ing different priorities may cause user fatigue, increase
barriers to data access, and without regular prompts may
reduce impact [34].
Nearly all suggestions for feedback modifications
presented were recommended for further evaluation of
effectiveness. This is not unexpected given the lack of
progress in the understanding of audit and feedback
mechanisms of actions or the key “active ingredients” to
produce change [13].
There were three main study limitations. Firstly, Delphi
consensus processes can produce but not guarantee the val-
idity of an agreed set of endorsements. For our purposes,
given uncertainties around the optimal design of an audit
and feedback implementation laboratory, we leveraged a
reasonably diverse range of stakeholder perspectives and
attained consensus for most statements within two rounds,
which lends legitimacy to our future plans.
Secondly, despite our best efforts, we did not achieve a
larger sample size. Less than a fifth of people invited
participated in the consensus process, raising the
Table 2 Recommendations for a primary care prescribing implementation laboratory (Continued)
No. Recommendation A&F researcher’s
(n = 5) score (1–9)
Medicine
optimization lead’s




(n = 4) score (1–9)
% Consensus
(n = 14)
30. Whether the frequency or the number of times
feedback is delivered affects achievement
6 7 7 79
31. Whether different visual interpretations of the
data are more effective
7 9 7.5 71
32. Whether feedback on its own is more (cost-)
effective than feedback delivered with
educational outreach or training
8 8 7 71
33. Whether different delivery methods of
providing feedback are more effective
7 7 8 71
Whether asking practitioners to document the
implications of changing practice is more effective
6 7 5.5 43
Involved in designing feedback reports
34. General practitioners 8 9 9 100
35. Primary care pharmacists 8 8 9 93
36. Medicine optimization leads 8 9 8.5 92
Clinical commissioners 6 6 7 46
Patient and public involvement experts 5 6 6 36
Italicized text indicates areas not reaching consensus
aAreas reaching consensus not for inclusion
Alderson et al. Implementation Science Communications             (2021) 2:3 Page 8 of 10
possibility that our respondents had unusually high in-
terests in audit and feedback or research and those not
participating felt unable to contribute expertise in this
area. The lowest response was from the audit and feed-
back “Metalab” mailing list of researchers (10% of those
invited). We surmise two possible reasons why this may
be: Firstly, the mailing list includes audit and feedback
researchers; however, it is also open to those interested
in audit and feedback more generally (e.g., quality
improvement staff) who may not have considered them-
selves to be experts and therefore did not feel the study
was appropriate for them. Secondly, the researchers and
experts on the mailing list have been collaborators in
our previous and planned work and considered them-
selves insufficiently distanced. The response rates for
medicine optimization leads and patients and public
group (33% and 40%, respectively) are more representa-
tive of survey responses generally. We were unable to
collect information on non-responders to determine
non-responder bias. We at least avoided any potential
attrition bias by ensuring complete participation in both
rounds. Moreover, we still achieved a reasonable overall
balance of participants.
Finally, we did not seek the views of primary care
providers in this study, although such views were repre-
sented in earlier work and within the audit and feedback
researchers, medicine optimization leads, and study
team. We did gain international perspectives from audit
and feedback researchers with emerging experience of
developing implementation laboratories in other health-
care contexts. Our patient and public participants also
had an experience of oversight for previous trials of
audit and feedback in primary care [19] and helped en-
sure that plans for an implementation laboratory took
account of public priorities. Future work should aim to
involve end-users, including physicians, in the interven-
tion and implementation laboratory design.
The key endorsements for developing a primary care
prescribing implementation laboratory concern the need
for specific prescribing data, offering feedback at the
lowest aggregate level, using opt-out consent for prac-
tices (although preferably waived), and developing online
dashboards connected to electronic health record sys-
tems. These endorsements fit with those suggested by
Brehaut et al. to optimize the effectiveness of audit and
feedback [35], although some received stronger support
than others. Most methods of presenting feedback were
recommended for effectiveness evaluation, reflecting
continuing uncertainty on how best to optimize audit
and feedback in routine service development. Different
variants of audit and feedback, such as using an average-
or high-performing comparator, have little or no cost
implications. This suggests that marginal gains in feed-
back effects, such as an additional 1% in effectiveness
(from 4 to 5%) in problematic prescribing, are likely to
be worthwhile at a population level and would be rela-
tively straightforward to test within an implementation
laboratory [21].
Conclusions
This small study has produced expert consensus-based
endorsements for the optimal design of an audit and
feedback implementation laboratory addressing high-
priority prescribing issues in UK primary care. Any success-
ful collaboration will depend on identifying shared priorities
and addressing practical and ethical considerations. An
implementation laboratory at scale may lead to the develop-
ment of the first national clinical audit to implement radical
incrementalism to improve effectiveness.
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